Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies.

Next Previous
Search
Trial Profile

Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RGB 286638 (Primary)
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Aug 2011 Actual initiation date (1 Nov 2011) added as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Status changed from not yet recruiting to withdrawn prior to recruitment (withdrawn prior to recruitment).
    • 07 Jun 2011 Planned initiation date changed from 1 Nov 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top